Chronic Lymphocytic Leukemia

CLL Case Review: IgHV-Unmutated Therapy Options

During a <em>Targeted Oncology </em>live case-based peer perspectives presentation, Anthony Mato, MD, MSCE, explained to a group of physicians the diagnostic workup and treatment considerations and decisions he makes when seeing a patient with chronic lymphocytic leukemia in the clinic.

High-Risk IgVH-Unmutated Chronic Lymphocytic Leukemia

William G. Wierda, MD, PhD,&nbsp;discussed the emerging role of small molecule combinations and fixed-duration treatments in patients with relapsed/refractory CLL.

William G. Wierda, MD, PhD, discusses data surrounding the use of ibrutinib in combination with venetoclax as a treatment option for patients with newly diagnosed CLL as well as relapsed CLL.

Matthew S. Davids, MD, MMSc, discusses methods for choosing between frontline therapies for patients with newly diagnosed CLL and highlighted anticipated research in the field.

A look back at all the&nbsp;FDA news&nbsp;that happened in March 2019, including several new approvals, a clinical hold, an orphan drug designation, and more.

Jacqueline C. Barrientos, MD, MS, discusses the role of acalabrutinib, a second-generation BTK inhibitor, that is available for patients with chronic lymphocytic leukemia, but not yet approved.

The combination regimen of venetoclax and obinutuzumab is seeking FDA approval; a supplemental new drug application has been submitted to the FDA&nbsp;for the combination as a treatment for patients with&nbsp;previously untreated chronic lymphocytic leukemia who also have coexisting medical conditions, according to an announcement from&nbsp;Genentech (Roche).

Jacqueline C. Barrientos, MD, MS, discusses emerging agents and combinations in CLL based on recent trial data.

Adding ibrutinib to&nbsp;CAR T-cell therapy led to improved responses in patients with relapsed/refractory chronic lymphocytic leukemia, according to preliminary findings presented at&nbsp;the 2019 Transplantation and Cellular Therapy Meetings.

Robert L. Ferris, MD, PhD, co-physician editor in chief of Targeted Therapies in Oncology, discusses exciting new findings and merit highlights reported in this month&#39;s issue.

Presentations at the 60th American Society of Hematology Annual Meeting &amp; Exposition were dominated by advancements in the treatment of chronic lymphocytic leukemia.

John F. Seymour, MBBS, PhD, discusses some emerging themes from recent research for targeted therapies as treatment of patients with chronic lymphocytic leukemia.

Lead iLLUMINATE study author Carol Moreno, MD, PhD, discusses the safety and efficacy results from the iLLUMINATE trial which led to the FDA approval of&nbsp;ibrutinib plus obinutuzumab in CLL.